AGL 37.99 Decreased By ▼ -0.03 (-0.08%)
AIRLINK 215.53 Increased By ▲ 18.17 (9.21%)
BOP 9.80 Increased By ▲ 0.26 (2.73%)
CNERGY 6.79 Increased By ▲ 0.88 (14.89%)
DCL 9.17 Increased By ▲ 0.35 (3.97%)
DFML 38.96 Increased By ▲ 3.22 (9.01%)
DGKC 100.25 Increased By ▲ 3.39 (3.5%)
FCCL 36.70 Increased By ▲ 1.45 (4.11%)
FFBL 88.94 No Change ▼ 0.00 (0%)
FFL 14.49 Increased By ▲ 1.32 (10.02%)
HUBC 134.13 Increased By ▲ 6.58 (5.16%)
HUMNL 13.63 Increased By ▲ 0.13 (0.96%)
KEL 5.69 Increased By ▲ 0.37 (6.95%)
KOSM 7.32 Increased By ▲ 0.32 (4.57%)
MLCF 45.87 Increased By ▲ 1.17 (2.62%)
NBP 61.28 Decreased By ▼ -0.14 (-0.23%)
OGDC 232.59 Increased By ▲ 17.92 (8.35%)
PAEL 40.73 Increased By ▲ 1.94 (5%)
PIBTL 8.58 Increased By ▲ 0.33 (4%)
PPL 203.34 Increased By ▲ 10.26 (5.31%)
PRL 40.81 Increased By ▲ 2.15 (5.56%)
PTC 28.31 Increased By ▲ 2.51 (9.73%)
SEARL 108.51 Increased By ▲ 4.91 (4.74%)
TELE 8.74 Increased By ▲ 0.44 (5.3%)
TOMCL 35.83 Increased By ▲ 0.83 (2.37%)
TPLP 13.84 Increased By ▲ 0.54 (4.06%)
TREET 24.38 Increased By ▲ 2.22 (10.02%)
TRG 61.15 Increased By ▲ 5.56 (10%)
UNITY 34.84 Increased By ▲ 1.87 (5.67%)
WTL 1.72 Increased By ▲ 0.12 (7.5%)
BR100 12,244 Increased By 517.6 (4.41%)
BR30 38,419 Increased By 2042.6 (5.62%)
KSE100 113,924 Increased By 4411.3 (4.03%)
KSE30 36,044 Increased By 1530.5 (4.43%)

Pakistan Pharmaceutical Manufacturers' Association (PPMA) Chairman Mansoor Dilawar said that around 40 to 50 medicines are in short supply, and the number would soon cross 100.

Dilawar told Business Recorder that over 40 life-saving drugs are not available after the pharma industry decided not to import raw materials because of GST imposition.

The medicines short in the market include Alp tablets used for anti-depression, Dexamethasone for asthma, cancer, and joint pain, Epitab for epilepsy, Nervin for depression, Epival, Fexet D, Nitronal, Ventoline tablets, and injections.

Moreover, Epival In, Myrin P, Ketasol Inj, Loprin, Silver tab, phenergen Elixir, Tixylix Lincitilus, Chlooriptics Drops, systane drops, Rivotril drops, Dormicum tablets, Winstor, Tritace, Sodamint, Schazobutil, Jardymet, and Brufen are reportedly short in the market.

Drugs: manufacturers demand increase in MRP, abolition of sales tax

Lomotil, Panadol, Tan Primolut B, Progynova, Stilnix, Glucobay, Zentel, Avor, Gravibinan, Syp Gaviscon, Lipofundin, and Sorbid Injection are also not available.

The PPMA chairman said that the industry was suspending production of low-margin items after the Federal Board of Revenue (FBR) imposed taxes that jacked up the industry’s cost of production by Rs60 billion to Rs70 billion.

“Pharma industry cannot pass on the higher cost of production to consumers because there is a cap on drug prices,” he said.

“So, the industry has been forced to suspend production of low-margin medicines, which have become un-viable after an increase in taxes,” Dilawar added.

Dilawar said that the industry is paying 17% refundable GST at the import stage.

"There's a non-refundable 1% tax on raw materials. And then the government has imposed a 1% on the sale of medicines. This will force the industry to pay taxes of Rs60 billion to Rs70 billion annually."

A few days ago, the PPMA chairman said that the pharmaceutical industry is awaiting sales tax refunds of Rs40 billion since January 16, 2022. However, the FBR has denied that there were any refunds stuck with the tax authority.

Comments

Comments are closed.